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doi:10.1016/j.jtcvs.2003.11.028364 The Journal of Thoracic and CardioObjectives: This study assesses the mechanisms of apoptosis in patients after
on-pump coronary artery bypass graft surgery and the potential involvement of the
endogenous cardiac peptide urocortin as a cardiomyocyte salvage mechanism. We
have previously described the mechanisms of apoptosis after ischemia-reperfusion
injury in the rat heart and shown that endogenous urocortin is cardioprotective. Here
we extend these findings to the human heart exposed to ischemic-reperfusion injury.
Methods: Two sequential biopsy specimens were obtained from the right atriums of
24 patients undergoing coronary artery bypass grafting at the start of grafting and 10
minutes after release of the aortic clamp. Apoptosis was identified by means of
immunocytochemical colocalization between terminal deoxynucleotidyl trans-
ferase–mediated nick end-labeling positivity and active caspase-3. Immunostaining
for active caspase-9 and caspase-8 was performed to identify the pathways of
apoptosis induction. Urocortin and adenosine triphosphate–dependent potassium
channel expression was also assessed by means of immunocytochemistry.
Results: Myocyte apoptosis (0.1% before coronary artery bypass grafting) was
increased after coronary artery bypass grafting and reperfusion and was greater in
patients with longer periods of cardioplegic arrest (3.3%  0.5% with 55 minutes
and 5.1%  0.9% with 85-100 minutes, P  .001). Processing of caspase-9 was
always more pronounced than that of caspase-8 (P  .05). Cardioplegic arrest was
also associated with increased urocortin expression (up to 29%  3.5% vs 3% in
samples obtained before coronary artery bypass grafting, P  .001) but only in
nonapoptotic myocytes. These and surrounding viable myocytes also showed in-
creased Kir6.1 adenosine triphosphate–dependent potassium channel expression.
Conclusions: Cardioplegic arrest and subsequent reperfusion result in cardiomyo-
cyte apoptosis, largely through mitochondrial injury, as well as exclusive urocortin
expression in viable cells. This finding might suggest a cardioprotective role for
endogenous urocortin in human subjects.
During cardiopulmonary bypass, cardioplegic arrest and subsequentreperfusion inevitably expose the heart to an iatrogenic ischemia-reperfusion injury (IRI). Although different cardioplegic tech-niques (crystalloid, cold blood, and warm blood cardioplegia)have been developed to prevent this injury,1 the protection givento the heart by cardioplegia is often inadequate, especially for
surgical procedures requiring prolonged cardiac arrest. Previous reports have
shown, for instance, that both crystalloid2,3 and cold blood cardioplegia4,5 are still
associated with functional and ultrastructural changes in cardiac myocytes and the
coronary circulation, although no corresponding data are yet available concerning
6warm blood cardioplegia.
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PApoptotic cell death has been implicated in the patho-
genesis of several cardiovascular diseases, including IRI.7
However, although apoptosis has been frequently proposed
as one mechanism sustaining the loss of ischemic-reper-
fused myocytes, no definitive evidence has been provided
thus far for the contribution of apoptosis to the iatrogenic
IRI associated with on-pump cardiac surgery.
The apoptotic process is mediated by activation of a
cascade of proteases (caspases) that are normally present as
inactive zymogens and that cleave substrates essential for
the maintenance of cellular integrity. This proteolytic cas-
cade can be initiated in 2 ways. Mitochondrial damage
results in activation of the apical caspase-9, whereas binding
of a specific ligand, such as Fas ligand, to its cognate death
receptor, Fas, leads to activation of caspase-8. These 2
upstream caspases subsequently activate downstream effec-
tor caspases, such as caspase-3 and caspase-7. We have
previously shown that in the isolated perfused rat heart
exposed to ischemia and reperfusion, apoptosis of endothe-
lial cells, which precedes that of myocytes,8 is initiated
solely by caspase-9 activation, whereas myocyte apoptosis
involves activation of both signaling pathways.9 Although
processing of both caspase-9 and caspase-8 has also been
described in the failing human myocardium,10 the relative
contribution of the aforementioned signaling pathways to
any apoptosis associated with cardioplegic arrest in the
human subjects is currently unknown.
Several molecules have also been shown to inhibit car-
diac apoptosis. One inhibitor, urocortin, is a 40-amino-acid
member of the corticotrophin-releasing factor family11 and
is endogenously expressed in the human heart.12 The coex-
pression of urocortin and its cognate receptor in cardiac
myocytes suggests that endogenous urocortin might exert
autocrine-paracrine effects on the normal and diseased hu-
man heart. Biologically active urocortin, for instance, is
released from isolated myocytes exposed to simulated isch-
emia and confers on the culture medium cardioprotective
properties that are abrogated by corticotrophin-releasing
factor receptor antagonists.13
This background encouraged us to evaluate the occur-
rence of apoptosis and the relative contribution of its sig-
naling pathways in human myocytes from patients exposed
to cardiopulmonary bypass, warm blood cardioplegia, and
subsequent reperfusion. Furthermore, we investigated
whether the above surgical IRI modifies the cardiac expres-




The study was approved by the Institutional Ethics Committee of
S. Rocco Hospital (Ome, Italy), and all patients selected provided
informed consent before enrollment. Twenty-four patients (11
The Journal of Thoracifemale patients and 13 male patients) admitted for elective on-
pump coronary artery bypass graft (CABG) surgery were classified
into one of 2 groups (groups A and B) on the basis of the duration
of cardioplegic arrest (Table 1). Aortic crossclamping time ranged
from 40 to 55 minutes (48  6 minutes [mean  SD]) for group
A (12 patients) and from 85 to 100 minutes (91  8 minutes) for
group B (12 patients) because of dissimilarities in coronary artery
anatomy (ie, intramyocardial, unusually small, or calcified coro-
nary arteries), although the mean number of grafts between the 2
groups was not significantly different (2.2 and 2.35 in groups A
and B, respectively; P  .05). The patients in both groups had
multiple-vessel coronary disease with symptoms of class II/III
according to the Canadian Cardiovascular Society Angina Classi-
fication. Exclusion criteria were as follows: (1) symptoms of
angina pectoris, heart failure, or both during the week preceding
the operation; (2) reduced left ventricular ejection fraction
(40%); (3) enlargement or hypertrophy of ventricular cardiac
chambers, atrial cardiac chambers, or both; (4) concomitant val-
vular disease; (5) arrhythmias; (6) diabetes and other metabolic
disorders; and (7) concomitant liver, pulmonary, or kidney dis-
eases. The intentional enrollment of subjects who were otherwise
healthy, unlike the patient population typically undergoing CAGB
surgery, although representing a limitation of our study, also has
the merit of restricting the degree of interference that comorbidi-
ties might have exerted. All the patients were receiving calcium
channel blockers and -blockers, which were discontinued to-
gether with all other medications 2 days before the operation. The
enrolled patients underwent multiple aortocoronary bypass grafts
with internal thoracic arteries and saphenous veins (Table 1).
Surgical Procedure
Anesthesia and muscle relaxation were induced with propofol
(2.0-2.5 mg/kg) and atracurium (0.08 mg/kg), respectively. Propo-
fol was continuously infused (4-6 mg · kg1 · h1) to maintain
anesthesia. Ventilation was controlled with 50% O2 in air. After
median sternotomy, the aorta and the inferior vena cava were
cannulated, and heparin (3 g/kg) was administered. Cardiopul-
monary bypass was conducted with nonpulsatile flow at a rate of
2.4 L · min1 · m2. After aortic crossclamping, intermittent
antegrade and retrograde warm blood cardioplegia was initiated
TABLE 1. Clinical characteristics of the enrolled patients
Variables Group A Group B
No. of patients 12 12
Female sex 7 5
Male sex 5 7
Age (y) 62 8 64 6
Aortic crossclamp time (min; mean  SD) 48 6 91 8
Range (min) 40-55 85-100
Grafts 3.8 0.6 4.0 0.8
LV ejection fraction (% before CAGB) 53 6 55 8
LV ejection fraction (% after CABG) 51 11 52 13
Data are expressed as means  SD.
LV, Left ventricular; CABG, coronary artery bypass grafting.through the infusion of whole blood plus 20 mEq/L of potassium.
c and Cardiovascular Surgery ● Volume 128, Number 3 365
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CSPThe cardioplegic solution was injected at 37°C for 2 minutes into
the aortic root (flow rate, 300 mL/min) and then for an additional
2 minutes into the coronary sinus at approximately 150 mL/min
(approximately 40 mm Hg). This dose of cardioplegic solution was
injected every 15 to 20 minutes, partially antegrade followed by
retrograde. Cardiopulmonary bypass was maintained with moder-
ate hemodilution (hematocrit, 24%-28%). After completion of the
distal anastomoses, the aortic crossclamp was removed, and the
construction of the proximal anastomoses was begun. At the end of
the grafting procedure, protamine (3 g/kg) was injected to reverse
Figure 1. A, Control precardioplegic heart (group A)
caspase-3. Orange nuclei are stained with propidium
no processing of caspase-8 or caspase-9. Cells are c
heart (group A): yellow TUNEL-positive nuclei colocaliz
(bright red). D, Postcardioplegic heart (group B): ca
positive (yellow/green nuclei) and cytoplasmic anti-
magnifications: A, B, and C, 400; D, 650.)
TABLE 2. Percentages of TUNEL-, caspase-, urocortin-, and
and postcardioplegia biopsy specimens
Groups TUNEL Caspase-3 C
Pre-CP, group A 0% 0%
Pre-CP, group B 0% 0%
Post-CP, group A 3.3% 0.5%* 4.5% 0.8%* 1.5%
Post-CP, group B 5.1% 0.9%** 6.9% 1.1%** 3.2%
Data, in percentages  SD, are expressed as the means of 12 to 15 high
TUNEL, Terminal deoxynucleotidyl transferase–mediated nick end labeling
*P  .05, **P  .01, and ***P  .001 versus corresponding precardioplethe effect of heparin. Inotropic drugs were not used.
366 The Journal of Thoracic and Cardiovascular Surgery ● SeptTissue Sampling
Two sequential biopsy specimens were obtained from a virgin site
in the right atrium by the same experienced cardiac surgeon
(M.F.). The first biopsy specimen was taken as a control sample at
the start of cardiopulmonary bypass but before cardioplegia. The
second specimen was obtained as near as possible to the site of the
previous sampling about 10 minutes after the release of the aortic
crossclamp. There were no clinical complications related to the
sampling procedure. Immediately after collection, a section of the
biopsy material was fixed in 4% formaldehyde and stored at 4°C
ibiting no TUNEL-positive staining or processing of
e. B, Control precardioplegic heart (group B) showing
erstained with propidium iodide. C, Postcardioplegic
th cytoplasmic anti-active caspase-3–positive labeling
myocytes showing colocalization between TUNEL-
e caspase-3–positive staining (bright red). (Original
.1-positive labeling in cardiac myocytes in precardioplegia
e-8 Caspase-9 Urocortin Kir6.1
0% 2.3% 0.5% 0.9% 0.3%
0% 1.9% 0.4% 0.6% 0.2%
.4%* 4.3% 1.2%* 17% 2.3%*** 2.3% 0.6%*















; CP,for a maximum of 48 hours. The remainder was promptly
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Pcollected in cryovials, snap-frozen in liquid nitrogen, and stored
at 80°C.
Immunocytochemistry Assessment
Serial 5-m sections were cut from paraffin blocks, and after
dewaxing and heat-mediated antigen retrieval, they were stained
with terminal deoxynucleotidyl transferase–mediated nick end-
labeling (TUNEL) reagents, propidium iodide, and an antibody
against the cleaved active form of caspase-3 (Santa Cruz Biotech-
nology, Inc, Santa Cruz, Calif), as previously described.8 Colocal-
ization of cleaved caspase-3 and TUNEL-positive staining was
used as marker of myocyte cell apoptosis. Other myocardial sec-
tions were stained with an antibody recognizing the cleaved form
of caspase-8 or caspase-9 (BioVision, Mountain View, Calif) and
subsequently counterstained with propidium iodide. In another
staining reaction, after TUNEL staining, serial myocardial sections
were incubated with an antibody against urocortin or the Kir6.1
adenosine triphosphate–dependent potassium (KATP) channel sub-
unit (Santa Cruz Biotechnology, Inc) and, where appropriate,
counterstained with propidium iodide. After washing and incuba-
tion with suitable secondary antibodies (DakoCytomation,
Figure 2. Processing of caspase-3 (C3), caspase-8 (C8), and
caspase-9 (C9) in precardioplegic (pre-CP) and postcardioplegic
(post-CP) samples from groups A and B analyzed by means of
Western blotting. The housekeeping gene actin was used as a
protein-loading control.Glostrup, Denmark), sections were analyzed by a confocal micros-
The Journal of ThoraciFigure 3. Serial myocardial sections from a postcardioplegic
heart (group B) showing activation of caspase-9 (B, bright red)
and caspase-8 (C, bright green) in cardiac myocytes, as identified
by an anti-desmin red banding running perpendicularly to the cell
bodies (A). (Original magnification 400.)
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CSPcopist who was blinded to the origin and sequence of the speci-
mens (T.M.S.). Data were expressed as the means of 12 to 15
high-power fields  SD.
Western Blotting
Cardiac specimens before and after cardioplegia from both groups
of patients were homogenized in lysis buffer, electrophoresed on
8% sodium dodecylsulfate–polyacrylamide gels, and Western blot-
ted with anti-active caspase-3, caspase-8, and caspase-9 antibod-
ies, as previously described.9
Statistical Analysis
Significance was evaluated by using the 2-tailed analysis of vari-
ance test.
Results
As shown in Figure 1, A and B, in the control precardiople-
gic specimens from patients assigned to both groups, there
was no TUNEL staining or processing of any tested
caspases. The absence of cleavage of caspase-3, caspase-8,
and caspase-9 was also seen in frozen samples processed by
means of Western blotting. After 40 to 55 minutes of
cardioplegic arrest followed by 10 minutes of reperfusion
Figure 4. Basal expression of urocortin in cardiac my
cells are detected (B). Postcardioplegic heart (group B
staining (bright red) are consistently TUNEL negative. T
are recognizable by the anti-desmin red banding runnin
magnification 400.)(group A), the proportion of TUNEL-positive myocytes was
368 The Journal of Thoracic and Cardiovascular Surgery ● Sept3.3%  0.5% (P  .001). TUNEL- and cleaved caspase-
3–positive staining was consistently colocalized, although
not all cells labeled by the anti-active caspase-3 antibody
were TUNEL positive (Figure 1, C and D). In patients from
group B exposed to roughly twice the duration of cardiople-
gic arrest followed by 10 minutes of reperfusion, the num-
ber of cardiac myocytes labeled by means of TUNEL stain-
ing was significantly increased compared with that in group
A (5.1%  0.9%, P  .001). A significant correlation (P 
.001) was observed between the magnitude of myocyte cell
apoptosis and the length of aortic crossclamp time. A par-
allel increase in the proportion of cardiac myocytes showing
activation of initiator caspases was also observed. By means
of immunocytochemistry, processing of caspase-9 was
more pronounced than that of caspase-8 both in group A and
group B (Figure 2). However, the level of caspase-8 acti-
vation was consistently higher in the hearts from group B,
which were exposed to a longer cardioplegia time compared
with those of group A (Table 2). Similarly, by means of
Western blotting, processing of caspase-3 was observed in
all the biopsy samples exposed to cardioplegia-reperfusion.
Additionally, in the same specimens, cleavage of caspase-9
es from a control heart (group A). No TUNEL-positive
rdiac myocytes exhibiting cytosolic urocortin-positive
L-positive nuclei appear yellow (D). Cardiac myocytes
rpendicularly to their cellular body (A and C). (Originalocyt
): ca
UNE
g pewas more marked than that of caspase-8 (Figure 3).
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PThe basal level of urocortin expression detected in con-
trol specimens was less than 3% in both groups (Table 2).
However, cardioplegia followed by reperfusion greatly en-
hanced urocortin expression in a time-dependent manner. In
tissue samples from group A and group B, 17% 2.3% and
29%  3.5% of cardiac myocytes, respectively, exhibited
cytoplasmic positive staining for urocortin, with the in-
creased expression in group B being significantly (P 
.001) greater than that in group A.
Myocytes expressing urocortin at the protein level
showed no TUNEL-positive staining, suggesting that en-
dogenous urocortin effectively protects those myocytes in
which it is produced (Figure 4, A and B). Among a total of
156 urocortin-positive cells examined, only 2 showed weak
TUNEL positivity. Correspondingly, none of the 83
TUNEL-positive myocytes observed expressed urocortin.
In addition, urocortin-positive, TUNEL-negative myocytes
were surrounded by a cuff of urocortin- negative, TUNEL-
negative cells (Figure 4, C and D).
In specimens from group B only, the myocytes overex-
pressing urocortin were also labeled by an antibody specific
for the Kir6.1 cardiac KATP channel subtype. In these sam-
ples, urocortin-positive cells were surrounded by a cuff of
TUNEL- and urocortin-negative myocytes but that also
expressed the Kir6.1 cardiac KATP channel subunit (Figure
5).
Discussion
This study demonstrates that effector caspase activation and
DNA fragmentation are produced after cardiopulmonary
bypass in human myocytes despite warm blood cardioplegia
and that the degree of myocardial apoptosis is dependent on
the duration of cardioplegic arrest. Apoptosis appears to
mostly reflect mitochondrial injury because activation of
caspase-9 was predominant over that of caspase-8, irrespec-
tive of the length of cardioplegia. Urocortin expression was
increased in human cardioplegic hearts, and cells expressing
urocortin were nonapoptotic. Moreover, viable urocortin-
positive myocytes were surrounded by a ring of urocortin-
negative cells, which, however, expressed the Kir6.1 com-
ponent of the KATP channel.
The finding that all TUNEL-positive cells were also
stained with an antibody recognizing the active form of
caspase-3 confirms that these cells were apoptotic because
they exhibited 2 distinct hallmarks of apoptosis: DNA frag-
mentation and caspase activation. However, other active
caspase-3–positive cells were TUNEL negative. It is likely
that these latter cells, sampled in a single time window,
were undergoing apoptosis but had not yet developed the
final stage of DNA fragmentation, and this appears to be
even more verisimilar after shorter periods of cardioplegic
arrest. The numbers of TUNEL-positive cells reported here
might therefore underestimate the true level of apoptosis
The Journal of ThoraciFigure 5. Serial atrial sections from a postcardioplegic heart
(group B). Induction of urocortin in cardiac myocytes (B, bright
red cytosolic staining) is associated with TUNEL negativity (A,
TUNEL-positive nuclei appear yellow) and overexpression of the
Kir6.1 potassium channel (bright green cytosolic staining), which
is detected not only in urocortin-positive cells but also in uro-
cortin-negative neighboring cells (C). Cardiac myocytes are la-
beled by an anti-desmin antibody (A). (Original magnification
400.)
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CSPcaused by cardioplegic arrest. Ventricular myocytes from
patients with ischemic cardiomyopathy have been shown to
be more susceptible than are normal myocytes to caspase-3
cleavage induced by hypoxia in vitro,14 and thus preceding
ischemic pathology might have contributed to the levels of
apoptosis observed in the present study.
This study confirms that in patients undergoing on-pump
cardiac surgery, cardioplegia might ameliorate but does not
totally inhibit myocyte apoptosis. Indeed, DNA fragmenta-
tion, mitochondrial cytochrome c release, and morphologic
changes characteristic of apoptosis have previously been
demonstrated in atria from human hearts exposed to cold
cardioplegia,2,3 although atrial changes might not fully re-
flect cell death in ventricular myocytes. Indeed, atrial tissue
might be suboptimally protected and therefore at greater
risk of cellular injury and death. However, the initiating
pathways sustaining myocyte apoptosis have not been de-
fined. We have previously shown, in the ischemic-reper-
fused rat heart, that endothelial cell apoptosis precedes that
of myocytes8 and is exclusively mediated by activation of
caspase-9.9 Subsequent myocyte apoptosis during reperfu-
sion is also initially mediated by caspase-9 activation, al-
though cleavage of caspase-8 consistently increases with
longer reperfusion times. Although the apparent differential
kinetics of caspase-9 and caspase-8 activation in the human
heart exposed to cardioplegic IRI might reflect different
affinities of the antibodies used, the earlier activation of
caspase-9 in human hearts is consistent with the rat data,
during the accumulation of which different caspase antibod-
ies were used.
In neonatal cultured rat cardiac myocytes, ischemia in-
creases urocortin mRNA abundance, and the peptide is
released into the culture medium.13 Ischemia-precondi-
tioned media are themselves cardioprotective, and the pro-
tective effect is abrogated by a urocortin receptor antago-
nist.13 Moreover, both in cultured myocytes and in the
isolated perfused rat heart, exogenous urocortin reduces cell
death and infarct size, respectively,13,15 and, in the intact
heart, promotes hemodynamic and bioenergetic recovery.16
These cardioprotective effects of endogenous and exoge-
nous urocortin are mediated by several mechanisms, includ-
ing activation of p42/44 mitogen-activated protein kinase,15
induction of hsp90,17 and increased expression of Kir 6.1
KATP channels.18 Mitochondrial KATP channels have been
shown to play a crucial role in ischemic preconditioning19
and in cardioprotection after IRI, including cardioplegic
arrest,20 and recent evidence suggests that Kir6.1 is local-
ized in mitochondria.21
Enhanced expression of urocortin and its concomitant
colocalization with TUNEL-negative cells after cardiople-
gic arrest (Figure 4, B) might suggest that in the human
subject, as in the rat, IRI results in self-limitation of its
consequences by inducing enhanced cardiac expression of
370 The Journal of Thoracic and Cardiovascular Surgery ● Septendogenous urocortin. However, other explanations of the
above-mentioned findings (eg, a more rapid degradation of
urocortin in apoptotic cells) cannot be currently excluded
and therefore should be considered. In addition, although
the human data are necessarily associative and do not prove
causation, the findings that viable urocortin-positive cells
express the Kir6.1 KATP channel and are surrounded by
viable urocortin-negative but Kir6.1-positive cells are sug-
gestive that autocrine and paracrine enhancement of KATP
channel expression by endogenously released urocortin is
also one mechanism of its cardioprotective function in the
human subject. However, although this hypothesis is well
supported by experimental data in the rat, further studies are
needed to prove such a causative protective pathway in the
human heart.
We thank Ms Kathleen Steiner for her meticulous support in
the preparation of this manuscript and Dr Ruth Moore for her
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